PharmARC - ASCO 2011 Twitter Analysis of Top Links Shared and Comments on Molecules (3rd through 7th june)

ASCO 2011 Twitter Analytics June 3 – 7, 2011, Chicago, Illinois Prepared by: PharmARC Analytic Solutions Rohit Kumar [email_address] +91 97314 58005

Contents ,[object Object],[object Object]

Top Links and Abstracts Shared (June 3 rd – 7 th )

Top Links Shared (1/4) ,[object Object],[object Object],Title URL Salient Points Cancer’s New Era Of Promise And Chaos http://blogs.forbes.com/matthewherper/2011/06/05/cancers-new-era-of-promise-and-chaos/ ,[object Object],[object Object],[object Object],NCI at ASCO 2011: Partnering for Progress http://www.cancer.gov/researchandfunding/meetings/2011asco?cid=Tasco_ocs ,[object Object],[object Object],Should Twitter be Restricted at Scientific Meetings? http://33charts.com/2011/06/twitter-restricted-meetings.html ,[object Object],[object Object],Ovarian Cancer Screening Does Not Appear to Reduce Risk of Ovarian Cancer Death http://digitalnewsrelease.com/index.php?q=JAMA_3792 ,[object Object],[object Object],Random attacks cause concern in Chicago http://www.chicagotribune.com/news/local/ct-met-mob-attacks-20110606,0,7509040.story?track=rss&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+chicagotribune%2Fnews%2Flocal+(Chicago+Tribune+news+-+Local+news) ,[object Object],[object Object],The University of Texas The M.D. Anderson Cancer Center http://physicianrelations.org/asco2011/ ,[object Object],[object Object]

Top Links Shared (2/4) Title URL Salient Points Scientific Meetings through the Lens of Twitter http://www.cancer.gov/ncicancerbulletin/053111/page7 ,[object Object],[object Object],[object Object],Novartis Oncology global site http://www.novartisoncology.com/media/?usertrack.filter_applied=true&NovaId=4029462017804965268 ,[object Object],[object Object],SaveMyFertility.org Home page http://savemyfertility.org/ ,[object Object],[object Object],Clinical Trials Day at ASCO http://chicago2011.asco.org/AbouttheMeeting/WhatsNewin2011/ClinicalTrialsDay.aspx ,[object Object],[object Object],[object Object],Amgen medical info page http://m.amgenmedinfo.com/home/support ,[object Object],[object Object],Direct-to-Consumer Genetic Testing: Personalized Medicine in Evolution http://www.genomicslawreport.com/wp-content/uploads/2011/06/ASCO-DTC-Abstract.pdf ,[object Object],[object Object],ASCO 2011 Annual Meeting schedule http://www.physicianrelations.org/default/pdfs/asco2011/docmpresentations.pdf ,[object Object],[object Object]

Top Links Shared (3/4) Title URL Salient Points ASCO Experiment: One-Stop Commenting for Cancer Research http://blog.wcgworld.com/2011/06/asco-experiment-one-stop-commenting-for-cancer-research ,[object Object],[object Object],[object Object],New Glioblastoma Cancer Vaccine Shows Promise in Phase 2 Trial http://www.ucsf.edu/news/2011/06/9970/new-glioblastoma-cancer-vaccine-shows-promise-phase-2-trial ,[object Object],[object Object],Personalized Therapy Benefits Late-Stage Cancer Patients in Clinical Trial http://www2.mdanderson.org/cancerwise/2011/06/personalized-cancer-therapy-benefits-late-stage-cancer-patients-in-clinical-trial.html#more ,[object Object],[object Object],“ The Cancer That Gives Cancer a Bad Name”: Important News on the Treatment of Advanced Melanoma http://www.cancer.org/AboutUs/DrLensBlog/post/2011/06/05/Important-News-on-the-Treatment-of-Advanced-Melanoma-The-Cancer-That-Gives-Cancer-a-Bad-Name.aspx#continue ,[object Object],[object Object],[object Object],Primary Care Doctors and Medical Oncologists Have Different Concerns About Providing Survivorship Care http://www.cancer.net/patient/Cancer+News+and+Meetings/ASCO+Annual+Meetings/Research+Summaries/Survivorship/Primary+Care+Doctors+and+Medical+Oncologists+Have+Different+Concerns+About+Providing+Survivorship+Care ,[object Object],[object Object],[object Object],[object Object]

Top Links Shared (4/4) Title URL Salient Points Melanoma: Ready for Takeoff http://curetoday.com/index.cfm/fuseaction/article.showArticleByTumorType/id/826/tumorCategory/Skin/article_id/1693 ,[object Object],[object Object],[object Object],The University of Texas MD Anderson Cancer Center Education Page http://www.mdanderson.org/education-and-research/education-and-training/schools-and-programs/graduate-medical-education/residency-and-fellowship-programs/index.html ,[object Object],[object Object],ASCO '11: Roche, Bristol Melanoma Drugs Shine http://www.thestreet.com/story/11142848/1/asco-11-roche-bristol-melanoma-drugs-shine.html ,[object Object],[object Object],The Genomic Era: We Have Reached A New Tipping Point In Cancer Research And Treatment http://www.cancer.org/AboutUs/DrLensBlog/post/2011/06/06/The-Genomic-Era-We-Have-Reached-A-New-Tipping-Point-In-Cancer-Research-And-Treatment.aspx#continue ,[object Object],[object Object],ASCO Wrap-Up: The Skinny on Cancer News From All Corners of the U.S. http://www.xconomy.com/national/2011/06/07/asco-wrap-up-the-skinny-on-cancer-news-from-all-corners-of-the-u-s/ ,[object Object],[object Object]

Top Abstracts Shared Title URL Salient Points Effect of screening on ovarian cancer mortality in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer randomized screening trial http://abstract.asco.org/AbstView_102_84255.html ,[object Object],[object Object],Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma http://abstract.asco.org/AbstView_102_80592.html ,[object Object],[object Object],OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) http://abstract.asco.org/AbstView_102_82822.html ,[object Object],[object Object],Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma http://abstract.asco.org/AbstView_102_82344.html ,[object Object],[object Object],NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer http://abstract.asco.org/AbstView_102_79126.html ,[object Object],[object Object],Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial http://abstract.asco.org/AbstView_102_79897.html ,[object Object],[object Object]

Tweets on Molecules (29 th May – 7 th June)

More than 15 Peak Tweets bevacizumab: the most buzzed drug at ASCO 2011 vemurafenib-ipilimumab: a new era for the melanoma treatment – BMS & Roche combination therapy

vemurafenib (PLX 4032) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Yervoy (ipilimumab) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Avastin (bevacizumab) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Tarceva (erlotinib) ,[object Object],[object Object],[object Object],[object Object],[object Object]

Revlimid (lenalidomide) ,[object Object],[object Object],[object Object],[object Object]

Glivec (imatinib) ,[object Object],[object Object],[object Object]

Alimta (pemetrexed) ,[object Object],[object Object],[object Object]

Zytiga (abiraterone) ,[object Object],[object Object],[object Object],[object Object]

Aromasin (exemestane) ,[object Object],[object Object],[object Object]

Other molecules ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

For further information on the analytics, please contact: Rohit Kumar Product Director [email_address] +91 97314 58005

PharmARC - ASCO 2011 Twitter Analysis of Top Links Shared and Comments on Molecules (3rd through 7th june)

Recommandé

Recommandé

Contenu connexe

Tendances

Tendances (20)

En vedette

En vedette (20)

Similaire à PharmARC - ASCO 2011 Twitter Analysis of Top Links Shared and Comments on Molecules (3rd through 7th june)

Similaire à PharmARC - ASCO 2011 Twitter Analysis of Top Links Shared and Comments on Molecules (3rd through 7th june) (20)

PharmARC - ASCO 2011 Twitter Analysis of Top Links Shared and Comments on Molecules (3rd through 7th june)